ArticleInternational journal of molecular sciences2021
Toxicity Profiling of Biosurfactants Produced by Novel Marine Bacterial Strains.
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Rhamnolipid-augmented medium enhances growth ofApplied and environmental microbiology · 2026Article
- Dirhamnolipids fromACS omega · 2026Article
- Biosurfactants as Antibiofilm Agents for Medical Devices: Mechanisms, Evidence and Integration into Infection Prevention and Control.Microorganisms · 2026Review
- Biosurfactants as next-generation antimicrobials: mechanistic insights and applications in antibiofilm strategies for combatting antimicrobial resistance.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Microbial Blue Bioprospecting: Exploring the Advances of Compounds Post-Discovery.Marine drugs · 2025Review
- Antioxidant Properties of Biosurfactants: Multifunctional Biomolecules with Added Value in Formulation Chemistry.Biomolecules · 2025Review
- Maintaining ocean ecosystem health with hydrocarbonoclastic microbes.ISME communications · 2025Review
- Harnessing the Potential of Biosurfactants for Biomedical and Pharmaceutical Applications.Pharmaceutics · 2023Review
- Glycolipid Biosurfactants in Skincare Applications: Challenges and Recommendations for Future Exploitation.Molecules (Basel, Switzerland) · 2023Review
- Biosurfactants: Forthcomings and Regulatory Affairs in Food-Based Industries.Molecules (Basel, Switzerland) · 2023Review
- Characterisation of cytotoxicity and immunomodulatory effects of glycolipid biosurfactants on human keratinocytes.Applied microbiology and biotechnology · 2023Article
- Microbial Biosurfactant as an Alternate to Chemical Surfactants for Application in Cosmetics Industries in Personal and Skin Care Products: A Critical Review.BioMed research international · 2023Review
- High-quality physiology ofFrontiers in bioengineering and biotechnology · 2023Article
- Phase Behaviour, Functionality, and Physicochemical Characteristics of Glycolipid Surfactants of Microbial Origin.Frontiers in bioengineering and biotechnology · 2022Review
- Non-Ionic Surfactants for Stabilization of Polymeric Nanoparticles for Biomedical Uses.Materials (Basel, Switzerland) · 2021Review
- Characterization and Cytotoxicity ofFrontiers in bioengineering and biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Surface active agents (SAAs), currently used in modern industry, are synthetic chemicals produced from non-renewable sources, with potential toxic impacts on humans and the environment. Thus, there is an increased interest for the identification and utilization of natural derived SAAs. As such, the marine environment is considered a promising source of biosurfactants with low toxicity, environmental compatibility, and biodegradation compared to their synthetic counterparts. MARISURF is a Horizon 2020 EU-funded project aiming to identify and functionally characterize SAAs, derived from a unique marine bacterial collection, towards commercial exploitation. Specifically, rhamnolipids produced by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.